96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01233960
(ClinicalTrials.gov)
November 29, 20102/11/2010Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseA Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's DiseaseCrohn's DiseaseDrug: adult human mesenchymal stem cellsMesoblast, Inc.NULLCompleted18 Years70 YearsAll73Phase 3United States;Australia;New Zealand
2NCT00543374
(ClinicalTrials.gov)
September 17, 200711/10/2007Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseA Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's DiseaseCrohn's DiseaseDrug: Placebo;Drug: PROCHYMAL adult human mesenchymal stem cellsMesoblast, Inc.NULLCompleted18 Years70 YearsAll98Phase 3United States;Canada
3NCT00482092
(ClinicalTrials.gov)
September 17, 200730/5/2007Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseA Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's DiseaseCrohn's DiseaseDrug: adult human mesenchymal stem cells;Drug: PlaceboMesoblast, Inc.NULLCompleted18 Years70 YearsAll330Phase 3United States;Australia;Canada;New Zealand
4NCT00294112
(ClinicalTrials.gov)
March 13, 200617/2/2006Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's DiseaseA Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune SuppressantsCrohn's DiseaseDrug: Prochymal™ adult human mesenchymal stem cells;Drug: adult human mesenchymal stem cellsMesoblast, Inc.NULLCompleted18 Years70 YearsAll10Phase 2United States